Wexford Capital’s Avadel Pharmaceuticals AVDL Stock Holding History

Wexford Capital’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-272,821	Closed	-$5.88M	–	176
2025 Q4	$5.88M	Buy	+272,821	New	+$5.3M	1.13%	14
2025 Q2	–	Sell	-92,310	Closed	-$723K	–	249
2025 Q1	$723K	Buy	+92,310	New	+$773K	0.19%	96
2014 Q2	–	Sell	-165,000	Closed	-$2.21M	–	116
2014 Q1	$2.21M	Buy	+165,000	New	+$1.77M	0.17%	87

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Wexford Capital's AVDL Position: Q1 2026 in Review

Wexford Capital sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 272,821 shares — an estimated $5.88M sold.

Wexford Capital first reported a position in AVDL in Q1 2014 and held it in 3 quarters. The position peaked at $5.88M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Wexford Capital reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Wexford Capital sold 272,821 Avadel Pharmaceuticals shares in Q1 2026, an estimated $5.88M.
Wexford Capital first reported a position in Avadel Pharmaceuticals in Q1 2014 and held it in 3 quarters.
Wexford Capital's Avadel Pharmaceuticals position peaked at $5.88M in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Wexford Capital's 13F filing for Q1 2026, filed 15 May 2026.